Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis

Study Overview
=================
Brief Summary
-----------------
Patients having juvenile idiopathic arthritis (according to ILAR criteria) with hip arthritis were divided into 3 groups. Group 1 received hip denervation and group 2 controlled and received a subcutaneous injection of saline, and group 3 received intra-articular triamcinolone. Outcome measures included pain, tenderness, range of motion, SOLAR, HARISS score. These outcomes were measured at baseline, 2 weeks, and 16 weeks

Detailed Description
-----------------
The aim of the study is to test the effect of denervation of the active hip in JIA and compare it with a placebo without changing systemic treatment during the study. Outcome measures included pain, range of motion, SOLAR score, and Harris functional score.

Official Title
-----------------
Hip Denervation in Juvenile Idiopathic Arthritis

Conditions
-----------------
Juvenile Idiopathic Arthritis, Hip Arthritis

Intervention / Treatment
-----------------
* Drug: Lidocaine
* Drug: Placebo
* Drug: Steroid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with JIA with unilateral hip arthritis Exclusion Criteria: hip involvement due to other causes including septic arthritis other connective tissue diseases Avascular necrosis

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Hip denervation group<br>This group will receive Lidocaine 2% block of the femoral and obturator genicular branches. | Drug: Lidocaine<br>* denervation of the obturator and femoral genicular branches by Lidocaine 2 %<br>* Other names: The active denervation group;|
| Placebo Comparator: control group<br>this group will receive saline injection subcutaneously at the same places. | Drug: Placebo<br>* an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group<br>* Other names: The control group;|
| Active Comparator: Steroid<br>This group with receiving an intra-articular injection of 80mg triamcinolone | Drug: Steroid<br>* Intra-articular injection of 80mg of triamcinolone<br>* Other names: The active steroid group;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in visual analogue scale | a scale from 0-100 will be used 0 means no pain 100 means the maximum pain | Baseline, 2 weeks and 16 weeks | 
| Change in range of motion | flexion, internal rotation, external rotation range will be calculated | Baseline, 2 weeks and 16 weeks | 
| Change in Harris functional score | 100 means best results and 0 means worst results | Baseline, 2 weeks and 16 weeks | 
| semiquantitative tenderness score | 0 means no tenderness and 3 means maximum tenderness | Baseline, 2 weeks and 16 weeks | 
| Change in SOLAR score | GSUS. 0 means the least synovitis and the maximum, PDUS, o means no PD and 3 the maximum | Baseline, 2 weeks and 16 weeks |